Role of supportive care in lung cancer

被引：3

作者：

Scotte, F. ^{[1
]}

Riquet, M. ^{[2
]}

Oudard, S. ^{[1
]}

机构：

[1] Hop Europeen Georges Pompidou, AP HP, Med Oncol Serv, F-75015 Paris, France

[2] Hop Europeen Georges Pompidou, AP HP, Serv Chirurg Thorac, F-75015 Paris, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2008年 / 64卷 / 02期

关键词：

supportive care; cancer; lung; toxicity; chemotherapy;

D O I：

10.1016/j.pneumo.2008.04.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Lung cancer is a bad prognostic illness with a limited survival and many side effects related to treatment used. Supportive care in cancer attends to enhance patient care among cancer and treatments suffering. Opioids are one of the most important treatments in the management of dyspnoea and pain. Every new drug in supportive care is tested to diminish side effects of treatment like erythropoietin against anemia or aprepitant against emesis. Many trials are developed to enhance this supportive care especially in lung cancer management. (C) 2008 Elsevier Masson SAS. Tous droits reserves.

引用

页码：118 / 124

页数：7

共 19 条

[1] EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours [J].

Aapro, M. S. ;

Cameron, D. A. ;

Pettengell, R. ;

Bohlius, J. ;

Crawford, J. ;

Ellis, M. ;

Kearney, N. ;

Lyman, G. H. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, D. C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2433-2453

[2] Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea [J].

Abernethy, AP ;

Currow, DC ;

Frith, P ;

Fazekas, BS ;

McHugh, A ;

Bui, C .

BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :523-526

[3]

[Anonymous], 2005, DHOSSDO2005101

[4] Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study [J].

Berrino, Franco ;

De Angelis, Roberta ;

Sant, Milena ;

Rosso, Stefano ;

Lasota, Magdalena B. ;

Coebergh, Jan W. ;

Santaquilani, Mariano .

LANCET ONCOLOGY, 2007, 8 (09) :773-783

[5] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update [J].

Bokemeyer, C. ;

Aapro, M. S. ;

Courdi, A. ;

Foubert, J. ;

Link, H. ;

Osterborg, A. ;

Repetto, L. ;

Soubeyran, P. .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) :258-270

[6] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

Pazdur, R .

ONCOLOGIST, 2003, 8 (04) :303-306

[7]

Currow David C, 2007, Curr Opin Support Palliat Care, V1, P96, DOI 10.1097/SPC.0b013e3282ef5e03

[8] Pulmonary toxicity from novel antineoplastic agents [J].

Dimopoulou, I ;

Bamias, A ;

Lyberopoulos, P ;

Dimopoulos, MA .

ANNALS OF ONCOLOGY, 2006, 17 (03) :372-379

[9] Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma [J].

Frangie, Carlos ;

Lefaucheur, Carmen ;

Medioni, Jacques ;

Jacquot, Christian ;

Hill, Garry S. ;

Nochy, Dominique .

LANCET ONCOLOGY, 2007, 8 (02) :177-178

[10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

← 1 2 →